The Fraser Institute has released its 2012 Report: Access Delayed Access Denied.
Though the report is not specifically about cancer drugs, the situation is similar in many respects.
Highlights of the report include:
- On average, Canadians wait two over years for access to new drugs due to federal delays in approving them and provincial delays in authorizing reimbursement
- Health Canada took longer than Europe (in all 7 years studied) and the US (in the past 6 of 7 years studied) to review drugs for marketing authorization, and the provincial approval process adds further delay
- On average, only 23% of the new drugs that Health Canada certified as safe and effective between 2004 and 2010 have been declared eligible for reimbursement under provincial public drug programs as of January 1st, 2012
- Private-sector drug insurance plans have provided reimbursement for 84% of new drugs approved by Health Canada from 2004 to 2010 (as of January 1st, 2012), and have covered them more rapidly than public drug insurance
You can access the full report here.